Dr. Erdal Karaoz

Dr. Erdal Karaoz |Clyto Access

Liv Hospital, Center for Regenerative Medicine and Stem Cell Research & Manufacturing (LivMedCell)

Keynote Speaker




Title: Stem Cell Applications on Neuro-Muscular Degenerative Disorders: Bench to Bedside

Abstract: Recent insights into stem cell (SC) biology promise the regeneration of damaged organs. Stem cells (SCs) have the capability of self-renewal and differentiation into a wide range of cell types with various potential clinical and therapeutic applications. SCs are providing hope for many diseases that are currently in need of effective therapeutic methods, including neurodegenerative disorders like; stroke, amyotrophic lateral sclerosis, Alzheimer’s disease, Parkinson’s disease and as well as muscular dystrophy disorders like Duchene Muscular Dystrophy and Facio-scapulo-humeral Muscular Dystrophy. For this aim, numerous pre-clinical studies have been achieved and\or in progress on different types of stem cells including, induced pluripotent stem cell (IPS), embryonic stem cell (ESC) and neural stem cells. But there are some complications on the clinical utilization of these cells, due to the reason of ethical issues and especially because of the potential of formation of teratomas via IPSs and ESCs. For this reason, as we glance to the clinical trials ongoing nowadays, we see that mesenchymal stem cells (MSCs) are studied intensely on clinical applications. MSCs attracted particular interest because of their ease of isolation, characterization, apparent multipotency and pleiotropic effects. MSCs are capable of self-renewal and differentiation into specialized cell types and thus have the potential to promote organogenesis, tissue regeneration, maintenance and repair. In addition to their capability of regulating inflammation, they can promote other beneficial effects, such as neuronal growth, decreasing free radicals, reducing apoptosis and releasing different neurotrophic factors which can assist the endogenous regeneration of the injured region. MSC studies in various disease models, including cardiovascular and neurodegenerative disorders, demonstrated their efficacy in attenuating organ injury.  Currently, more than 500 human clinical trials employing cell therapy for the treatment of diverse diseases, including cardiac, neurologic, immune and respiratory conditions, are ongoing or completed. The results of clinical trials carried out for the treatment of various diseases, especially including neuro-muscular degenerative disorders, via application of MSCs derived from different tissues and manufactured in our own GMP facility, will be introduced in this presentation. ,

Related Conferences :

Global Forum on Transplantation Research and Technologies